Results 51 to 60 of about 12,312 (182)

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

The deubiquitinase USP38 affects cellular functions through interacting with LSD1

open access: yesBiological Research, 2018
Background Deubiquitination is a posttranslational protein modification prevalent in mammalian cells. Deubiquitinases regulate the functions of the target protein by removing its ubiquitin chain.
Wenbin Liu   +3 more
doaj   +1 more source

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer

open access: yesMolecular Cancer, 2022
Background Histone lysine-specific demethylase 1 (LSD1) expression has been shown to be significantly elevated in gastric cancer (GC) and may be associated with the proliferation and metastasis of GC.
Dan-Dan Shen   +12 more
doaj   +1 more source

Strategies and mechanisms of precision genome engineering: From gene editing to genome writing

open access: yesiMetaOmics, EarlyView.
In this review, we examined the progression of genome manipulation from stochastic nuclease‐mediated cutting toward precise editing and programmable genome writing. We discussed tools like multi‐kilobase RNA‐guided integrators and Artificial Intelligence (AI)‐designed effectors and showed how these advances enable researchers to treat genomes as ...
Kerui Huang   +19 more
wiley   +1 more source

Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors

open access: yesActa Pharmaceutica Sinica B, 2020
Histone lysine specific demethylase 1 (LSD1) has become a potential therapeutic target for the treatment of cancer. Discovery and develop novel and potent LSD1 inhibitors is a challenge, although several of them have already entered into clinical trials.
Liying Ma   +7 more
doaj   +1 more source

Glucose Activates Lysine-Specific Demethylase 1 through the KEAP1/p62 Pathway

open access: yesAntioxidants, 2021
Endometrial cancer incidence increases annually. Several risk factors, including high glucose intake, are associated with endometrial cancer. We investigated whether glucose affects lysine-specific demethylase 1 (LSD1) expression and the responsible ...
Chiao-Yun Lin   +8 more
doaj   +1 more source

Experiencing 50 Years of Synergistic Development in Structural Biology and Enzymology

open access: yesJournal of the Chinese Chemical Society, EarlyView.
Picture of Sunney Chan with Academia Sinica (AS) President James C. Liao and three Vice Presidents: Shin‐Kun Peng (left one), Tang K. Tang (right one), and Mei‐Yin Chou (right 2), taken at the annual Chinese New Year's Banquet of AS, February 7, 2025. This was likely Sunney's last appearance in formal activities of AS.
Ming‐Daw Tsai
wiley   +1 more source

Epigenetic repression of Cend1 by lysine-specific demethylase 1 is essential for murine heart development

open access: yesiScience
Summary: Epigenetic regulation of heart development remains incompletely understood. Here we show that LSD1, a histone demethylase, plays a crucial role in regulating cardiomyocyte proliferation during heart development.
Huahua Liu   +14 more
doaj   +1 more source

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

open access: yesJournal of Hematology & Oncology, 2016
Background Mixed lineage leukemia (MLL) gene translocations are found in ~75 % infant and 10 % adult acute leukemia, showing a poor prognosis. Lysine-specific demethylase 1 (LSD1) has recently been implicated to be a drug target for this subtype of ...
Zizhen Feng   +10 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy